drugset
Drugs / Dapagliflozin
last change 3 days ago re-read 2 minutes ago

Dapagliflozin

also known as DAPA · Forxiga · Farxiga · dapagliflozine · BMS -512148 · Dapagliflozin propanediol · A51R1 · ATB-1012 · +11 more

Small molecule targets OTUD1, SLC5A2 via inhibition

Developed for
type 2 diabetes mellitus · heart failure · chronic kidney disease · type 1 diabetes mellitus · diabetes mellitus · obesity disorder · diastolic heart failure · hypertensive disorder
+120 more · prediabetes syndrome · diabetic kidney disease · proteinuria · symptomatic heart failure · coronary artery disorder · end stage renal failure · acute kidney injury · atrial fibrillation · hyperglycemia · myocardial infarction · ST-elevation myocardial infarction · breast cancer · NAFLD1 · cardiovascular disorder · cirrhosis of liver · systolic heart failure · anemia · COVID-19 · disease related to solid organ transplantation · glucose intolerance · kidney failure · lupus nephritis · metabolic syndrome X · polycystic ovary syndrome · acute coronary syndrome · acute myocardial infarction · cardiomyopathy · chronic renal failure syndrome · congestive heart failure · cystinuria · dilated cardiomyopathy · Her2-receptor negative breast cancer · IgA glomerulonephritis · impaired renal function disease · intermediate coronary syndrome · ischemic stroke · metabolic dysfunction-associated steatohepatitis · metabolic dysfunction-associated steatotic liver disease · mitral valve insufficiency · morbid obesity · nephrotic syndrome · acute graft versus host disease · acute subendocardial myocardial infarction · advanced heart failure · AL amyloidosis · Alport syndrome · Alzheimer disease · amyloidosis · anemia due to chronic disorder · atherosclerosis · autosomal dominant polycystic kidney disease · brain cancer · calcinosis · cardiac valvular defect · cardio-renal syndrome · carotid artery disorder · chemotherapy-induced toxicity · childhood malignant neoplasm · cisplatin toxicity · cognitive impairment with or without cerebellar ataxia · congenital cardiovascular shunt · congenital heart malformation · coronary atherosclerosis · diabetic macular edema · diabetic retinopathy · diffuse secondary choroid atrophy · erectile dysfunction · Fabry disease · fibrotic liver disease · focal segmental glomerulosclerosis · glioma · glucose metabolism disease · hyperinsulinism · hypoglycemia · hypotensive disorder · infectious disease with sepsis · inherited kidney disorder · kidney disorder · left ventricular failure · Lewy body dementia · long COVID-19 · lung adenocarcinoma · lung cancer · malignant pancreatic neoplasm · metastatic prostate carcinoma · mild heart failure · mitral valve stenosis · myocardial ischemia · Parkinson disease · platelet disorder, undefined · preeclampsia · prostate carcinoma · pulmonary hypertension · rheumatic heart disease · sleep apnea syndrome · stroke disorder · tetralogy of fallot · univentricular cardiopathy · urolithiasis · aortic valve stenosis · atherosclerotic cardiovascular disease · cardiomyopathy due to anthracyclines · chronic hepatitis B virus infection · chronic thromboembolic pulmonary hypertension · critical illness polyneuropathy · depressive disorder · diabetic polyneuropathy · doxorubicin induced cardiomyopathy · essential hypertension · fatty liver disease · HIV infectious disease · inflammatory bowel disease · intrinsic cardiomyopathy · metabolic bone disorder · obstructive sleep apnea syndrome · pancreas disorder · pulmonary arterial hypertension · Tako-tsubo cardiomyopathy · vascular insufficiency disorder · vasculitis
Investigated by
AstraZeneca · Bristol-Myers Squibb · University Medical Center Groningen · Washington University School of Medicine · LG Chem · Astra Zeneca, Bristol-Myers Squibb
+380 more · Mansoura University · Mexican Social Security Institute · University of Guadalajara · Juvenile Diabetes Research Foundation · The George Institute · The University of Hong Kong · The University of Texas Health Science Center at San Antonio · University of Campinas, Brazil · AJU Pharm Co., Ltd. · Boryung Pharmaceutical Co., Ltd · Korea University Anam Hospital · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Parexel · University Health Network, Toronto · Uppsala University · Ain Shams University · Al-Azhar University · Beni-Suef University · Cairo University · Chang Gung Memorial Hospital · Children's Hospital of Fudan University · Christopher Bell · Kinderkrankenhaus auf der Bult · Mayo Clinic · National Institutes of Health (NIH) · National Taiwan University Hospital · Seoul National University Bundang Hospital · Yale University · Yonsei University · American Heart Association · Amsterdam UMC, location VUmc · Assistance Publique - Hôpitaux de Paris · Assiut University · Centre for Chronic Disease Control, India · Centro Universitario de Ciencias de la Salud, Mexico · Chong Kun Dang Pharmaceutical · Daewoong Pharmaceutical Co. LTD. · Damanhour University · Dong Wha Pharmaceutical Co. Ltd. · Dong-A ST Co., Ltd. · First Affiliated Hospital, Sun Yat-Sen University · Fundación para la Investigación del Hospital Clínico de Valencia · German Research Foundation · Hamad Medical Corporation · Hanmi Pharmaceutical Company Limited · Hospices Civils de Lyon · Institute of Liver and Biliary Sciences, India · Instituto de Salud Carlos III · Kyungsub Song · Medical University of Vienna · Nanfang Hospital, Southern Medical University · National Institute of Medical Sciences and Nutrition Salvador Zubiran · Northwestern University · Novartis Pharmaceuticals · Oman Ministry of Health · Ottawa Heart Institute Research Corporation · Peking Union Medical College Hospital · RemediumOne · RenJi Hospital · SK Chemicals Co., Ltd. · Shanghai Chest Hospital · Sun Yat-sen University · THPharm Corp. · Tan Tock Seng Hospital · The First Affiliated Hospital with Nanjing Medical University · The TIMI Study Group · Third Affiliated Hospital, Sun Yat-Sen University · University Medical Center Hamburg-Eppendorf · University of California, San Francisco · University of Chicago · University of Edinburgh · University of Glasgow · University of Michigan · all 386 on the full record

Regulatory milestones approvals, filings & regulatory actions · 10 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (8) US (FDA) FARXIGA — 2015-03-11 – 2024-06-12 fda.gov ↗
Approved US (FDA) FARXIGA — 2014-01-08 fda.gov ↗
Approved EU (EMA) Forxiga — 2012-11-11 europa.eu ↗

Trials 426 · started per year

today
EU approved 2012
US approved 2014
1
2
5
7
7
13
4
6
3
8
21
22
19
14
24
28
35
45
40
44
45
33
20062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 04 trials
Phase 0 NCT07235280 Dec 2025 → Jun 2028 expected lung adenocarcinoma Jonsson Comprehensive Cancer Center Recruiting No outcome recorded
Phase 0 NCT06373523 Sep 2024 → Jun 2025 overdue NAFLD1, fibrotic liver disease Post Graduate Institute of Medical Education and Research, Chandigarh Not yet recruiting No outcome recorded
Phase 0 NCT06812429 May 2024 → Apr 2025 — Washington University School of Medicine Completed No outcome recorded
Phase 0 NCT05262257 Apr 2022 → Dec 2023 type 2 diabetes mellitus The First Affiliated Hospital with Nanjing Medical University Unknown No outcome recorded
Phase 163 trials
Phase 1 NCT07396844 Jul 2026 overdue — LG Chem Not yet recruiting No outcome recorded
Phase 1 NCT07590466 May → Jul 2026 overdue hypertensive disorder, type 2 diabetes mellitus Autotelicbio Not yet recruiting No outcome recorded
Phase 1 NCT07404137 Feb → Apr 2026 — AstraZeneca Completed No outcome recorded
Phase 1 NCT07399470 Jan → Feb 2026 overdue — LG Chem Active not recruiting No outcome recorded
Phase 1 NCT07333742 Sep → Nov 2025 — LG Chem Completed No outcome recorded
Phase 1 NCT07044765 Aug → Nov 2025 overdue type 2 diabetes mellitus AJU Pharm Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT07034781 Aug → Nov 2025 overdue type 2 diabetes mellitus AJU Pharm Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT07083401 Jul 2025 → Jul 2026 overdue diabetes mellitus Boryung Pharmaceutical Co., Ltd Recruiting No outcome recorded
Phase 1 NCT07083388 Jul 2025 → Jul 2026 overdue diabetes mellitus Boryung Pharmaceutical Co., Ltd Recruiting No outcome recorded
Phase 1 NCT06979388 May → Jul 2025 — AstraZeneca Completed No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT07678203 May 2026 → Jan 2027 expected chronic kidney disease, lupus nephritis, systemic lupus erythematosus Hospital Civil Juan I. Menchaca Active not recruiting No outcome recorded
Phase 1/2 NCT05719714 Jan 2024 → Sep 2026 expected chronic kidney disease, diastolic heart failure Northwestern University Recruiting No outcome recorded
Phase 1/2 NCT06113900 Dec 2023 → Dec 2024 lupus nephritis Ain Shams University Unknown No outcome recorded
Phase 1/2 NCT04401904 Jun 2020 → Sep 2022 — The University of Texas Health Science Center at San Antonio Completed No outcome recorded
Phase 1/2 NCT03801642 Jan 2019 → Jul 2022 Alzheimer disease Jeff Burns, MD Completed No outcome recorded
Phase 265 trials
Phase 2 NCT07682350 Sep 2026 → Sep 2029 expected diabetes mellitus Odense University Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07516847 Sep 2026 → Jan 2029 expected anemia, myelodysplastic syndrome Seug yun Yoon, MD Not yet recruiting No outcome recorded
Phase 2 NCT07310433 Jun 2026 → Oct 2029 expected metastatic prostate carcinoma Yung NA Not yet recruiting No outcome recorded
Phase 2 NCT07273838 Mar 2026 → Aug 2028 expected acute kidney injury, heart failure Yale University Recruiting No outcome recorded
Phase 2 NCT06072326 Jan 2026 → Dec 2027 expected diabetic kidney disease University Medical Center Groningen Not yet recruiting No outcome recorded
Phase 2 NCT07222917 Dec 2025 → May 2027 expected chronic kidney disease AstraZeneca Recruiting No outcome recorded
Phase 2 NCT07174687 Dec 2025 → Dec 2027 expected diffuse secondary choroid atrophy, retinal degeneration Washington University School of Medicine Recruiting No outcome recorded
Phase 2 NCT06762964 May 2025 → Feb 2027 expected congenital cardiovascular shunt, diastolic heart failure, univentricular cardiopathy Mayo Clinic Recruiting No outcome recorded
Phase 2 NCT07018622 May 2025 → Sep 2026 expected cancer, cisplatin toxicity National Institute of Medical Sciences and Nutrition Salvador Zubiran Recruiting No outcome recorded
Phase 2 NCT06929169 May 2025 → Jul 2026 overdue end stage renal failure Maximo Agustin Schiavone Recruiting No outcome recorded
Phase 2/318 trials
Phase 2/3 NCT07684326 Jul 2026 → Jul 2027 expected — Beni-Suef University Recruiting No outcome recorded
Phase 2/3 NCT07214818 Nov 2025 → Jul 2026 overdue nephrotic syndrome Mansoura University Recruiting No outcome recorded
Phase 2/3 NCT07033585 Jun 2025 → Oct 2026 expected type 2 diabetes mellitus Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Active not recruiting No outcome recorded
Phase 2/3 NCT06783166 Aug 2024 → Jul 2025 overdue heart failure Mansoura University Recruiting No outcome recorded
Phase 2/3 NCT06111443 Dec 2023 → Nov 2026 expected atrial fibrillation Chang Gung Memorial Hospital Active not recruiting No outcome recorded
Phase 2/3 NCT05713851 Jan 2023 → Dec 2024 acute kidney injury, chronic kidney disease National Institute of Medical Sciences and Nutrition Salvador Zubiran Unknown No outcome recorded
Phase 2/3 NCT05676684 Sep 2022 → Nov 2024 diastolic heart failure University of Porto Completed No outcome recorded
Phase 2/3 NCT05406505 Apr 2022 → May 2023 heart failure Mansoura University Completed No outcome recorded
Phase 2/3 NCT06286878 Dec 2021 → Jul 2025 overdue acute coronary syndrome, cardiac ventricle disorder, diabetes mellitus, myocardial infarction University of Sao Paulo Recruiting No outcome recorded
Phase 2/3 NCT04764097 Jun 2021 → Jun 2025 cardiovascular disorder, end stage renal failure Tan Tock Seng Hospital Withdrawn No outcome recorded
Phase 3104 trials
Phase 3 NCT06907251 Sep 2026 → Jun 2028 expected COVID-19, long COVID-19 Ottawa Heart Institute Research Corporation Not yet recruiting No outcome recorded
Phase 3 NCT07662109 Jul 2026 → Jul 2028 expected type 2 diabetes mellitus AstraZeneca Recruiting No outcome recorded
Phase 3 NCT07662044 Jul 2026 → Jul 2028 expected type 2 diabetes mellitus AstraZeneca Recruiting No outcome recorded
Phase 3 NCT07056699 Jul 2026 → Jun 2027 expected type 1 diabetes mellitus The University of Texas Health Science Center at San Antonio Recruiting No outcome recorded
Phase 3 NCT07488689 Jul 2026 → Aug 2029 expected infectious disease with sepsis University Hospital, Strasbourg, France Not yet recruiting No outcome recorded
Phase 3 NCT07569640 Jun 2026 → Dec 2028 expected symptomatic heart failure Washington University School of Medicine Not yet recruiting No outcome recorded
Phase 3 NCT07598864 May 2026 → May 2027 expected diabetic kidney disease Chittagong Medical College Not yet recruiting No outcome recorded
Phase 3 NCT06405178 Mar 2026 polycystic ovary syndrome Beni-Suef University Completed No outcome recorded
Phase 3 NCT07297589 Dec 2025 → Jan 2027 expected ST-elevation myocardial infarction Mexican Social Security Institute Recruiting No outcome recorded
Phase 3 NCT07295223 Dec 2025 → Aug 2026 overdue ST-elevation myocardial infarction Mexican Social Security Institute Recruiting No outcome recorded
Phase 4136 trials
Phase 4 NCT07342764 Sep 2026 → Nov 2028 expected — Sultan Qaboos University Not yet recruiting No outcome recorded
Phase 4 NCT07631156 Jun 2026 → Jun 2029 expected left ventricular failure, symptomatic heart failure Kyungsub Song Not yet recruiting No outcome recorded
Phase 4 NCT07572032 May 2026 → May 2028 expected cardiac valvular defect, coronary artery disorder, heart failure Kyungsub Song Recruiting No outcome recorded
Phase 4 NCT07405216 Apr 2026 → May 2027 expected chronic kidney disease, proteinuria Centenario Hospital Miguel Hidalgo Recruiting No outcome recorded
Phase 4 NCT07482943 Apr 2026 → Apr 2028 expected heart failure The University of Hong Kong Not yet recruiting No outcome recorded
Phase 4 NCT07513883 Mar 2026 → Sep 2028 expected heart failure Ziekenhuis Oost-Limburg Recruiting No outcome recorded
Phase 4 NCT07351643 Feb → Oct 2026 expected acute coronary syndrome Shenyang Northern Hospital Not yet recruiting No outcome recorded
Phase 4 NCT07614230 Jan 2026 → Jun 2027 expected atherosclerosis, coronary artery disorder, type 2 diabetes mellitus Junjie Yang Recruiting No outcome recorded
Phase 4 NCT07311551 Dec 2025 → Dec 2026 expected type 2 diabetes mellitus Bhavya Bhavya, MD Not yet recruiting No outcome recorded
Phase 4 NCT07108985 Sep 2025 → Sep 2029 expected hyperglycemia, type 2 diabetes mellitus Yonsei University Not yet recruiting No outcome recorded
Show all 136 trials opens the full record — a long page
Phase not applicable31 trials
— NCT07595289 Aug → Dec 2026 expected type 2 diabetes mellitus The Third Xiangya Hospital of Central South University Not yet recruiting No outcome recorded
— NCT07679828 Jul 2026 → Dec 2029 expected diabetes mellitus, hyperlipidemia, hypertensive disorder China Medical University, China Not yet recruiting No outcome recorded
— NCT07491042 Apr → Sep 2026 expected end stage renal failure Oman Ministry of Health Recruiting No outcome recorded
— NCT07392788 Apr 2026 → Dec 2027 expected symptomatic heart failure Centre Hospitalier Universitaire de Besancon Not yet recruiting No outcome recorded
— NCT07403955 Feb 2026 → Dec 2027 expected congestive heart failure Qilu Hospital of Shandong University Not yet recruiting No outcome recorded
— NCT07331727 Jan → Sep 2026 expected atrial fibrillation Shanghai Chest Hospital Not yet recruiting No outcome recorded
— NCT07272057 Dec 2025 → Oct 2026 expected lung cancer Shanghai Chest Hospital Not yet recruiting No outcome recorded
— NCT07204743 Aug 2025 → Jun 2026 overdue proteinuria Al-Quds University Active not recruiting No outcome recorded
— NCT06740786 Dec 2024 → May 2026 overdue atrial fibrillation Xu Liu Not yet recruiting No outcome recorded
— NCT06719661 Dec 2024 → May 2025 type 2 diabetes mellitus University of Sulaimani Completed No outcome recorded
Also used as a comparator or background therapy in 184 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT04780438 Comparator Sep 2021 → Sep 2023 atrial fibrillation G.Gennimatas General Hospital Unknown No outcome recorded
Phase 0 NCT04806633 Comparator Apr 2021 → Sep 2023 acute kidney injury G.Gennimatas General Hospital Unknown No outcome recorded
Phase 111 trials
Phase 1 NCT06759909 Comparator Jan 2025 → Dec 2026 expected atrial fibrillation Assiut University Not yet recruiting No outcome recorded
Phase 1 NCT06639087 Comparator Sep 2024 → May 2025 heart failure, impaired renal function disease AstraZeneca Terminated No outcome recorded
Phase 1 NCT05217654 Comparator Feb 2022 → Feb 2023 vascular insufficiency disorder Medical University of Vienna Unknown No outcome recorded
Phase 1 NCT04856969 Comparator Mar → May 2021 — Autotelicbio Completed No outcome recorded
Phase 1 NCT03216278 Comparator Sep 2017 → May 2018 — AstraZeneca Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT07239011 Comparator Nov 2025 → Nov 2026 expected depressive disorder Tanta University Recruiting No outcome recorded
Phase 1/2 NCT07020377 Comparator Jan 2024 → Dec 2025 overdue NAFLD1, type 2 diabetes mellitus Amira Bisher,PhD Active not recruiting No outcome recorded
Phase 1/2 NCT05965934 Background Jul 2023 → Dec 2024 heart failure Sequana Medical N.V. Unknown No outcome recorded
Phase 1/2 NCT04545411 Comparator Feb 2021 → Feb 2022 type 1 diabetes mellitus University of California, San Diego Completed No outcome recorded
Phase 225 trials
Phase 2 NCT07539259 Comparator Dec 2026 → Aug 2029 expected aortic valve stenosis University College, London Not yet recruiting No outcome recorded
Phase 2 NCT07610174 Background Jun 2025 → Apr 2026 cardiac valvular defect, heart failure Kafrelsheikh University Completed No outcome recorded
Phase 2 NCT06942910 Comparator May 2025 → Jul 2026 overdue chronic kidney disease AstraZeneca Recruiting No outcome recorded
Phase 2 NCT06427226 Comparator Oct 2024 → Oct 2026 expected breast cancer, doxorubicin induced cardiomyopathy Tanta University Recruiting No outcome recorded
Phase 2 NCT06888505 Comparator Sep 2024 → Sep 2025 cardiomyopathy due to anthracyclines, chemotherapy-induced toxicity Hawler Medical University Completed No outcome recorded
Phase 2/37 trials
Phase 2/3 NCT07469722 Background Mar 2026 → Jan 2028 expected congestive heart failure Hospital de Clinicas de Porto Alegre Not yet recruiting No outcome recorded
Phase 2/3 NCT05986136 Comparator Aug 2023 → Aug 2027 expected inflammatory bowel disease Mostafa Bahaa Recruiting No outcome recorded
Phase 2/3 NCT05162690 Comparator May 2022 → Dec 2023 diabetic polyneuropathy Post Graduate Institute of Medical Education and Research, Chandigarh Unknown No outcome recorded
Phase 2/3 NCT05241431 Comparator Feb 2022 → Mar 2024 aortic valve stenosis, intrinsic cardiomyopathy University of Aarhus Unknown No outcome recorded
Phase 2/3 NCT05424315 Comparator Oct 2021 → Apr 2022 myocardial infarction Omar Younis Completed No outcome recorded
Phase 341 trials
Phase 3 NCT07624305 Comparator Sep 2026 → Jul 2030 expected chronic kidney disease AstraZeneca Not yet recruiting No outcome recorded
Phase 3 NCT07392151 Background Feb 2026 → Oct 2029 expected coronary atherosclerosis, prediabetes syndrome Michael Mæng Not yet recruiting No outcome recorded
Phase 3 NCT07025629 Comparator Dec 2025 → Jan 2029 expected chronic kidney disease Assistance Publique - Hôpitaux de Paris Recruiting No outcome recorded
Phase 3 NCT07082114 Comparator Jul 2025 → Feb 2027 expected type 2 diabetes mellitus Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT06677060 Background Mar 2025 → Dec 2029 expected heart failure AstraZeneca Recruiting No outcome recorded
Phase 469 trials
Phase 4 NCT07323524 Comparator May 2026 → Jul 2029 expected lupus nephritis Brigham and Women's Hospital Recruiting No outcome recorded
Phase 4 NCT07436663 Comparator Feb 2026 → Nov 2027 expected breast cancer Tanta University Not yet recruiting No outcome recorded
Phase 4 NCT07351864 Background Jan → Apr 2026 overdue heart failure Mansoura University Not yet recruiting No outcome recorded
Phase 4 NCT07147114 Background Nov 2025 → Sep 2027 expected mild heart failure, pulmonary hypertension Gachon University Gil Medical Center Recruiting No outcome recorded
Phase 4 NCT06954090 Comparator Nov 2025 → Nov 2026 expected diabetic kidney disease, proteinuria, type 2 diabetes mellitus Steno Diabetes Center Copenhagen Enrolling by invitation No outcome recorded
Phase not applicable25 trials
— NCT07331220 Background Dec 2026 → Dec 2028 expected diastolic heart failure Nanjing First Hospital, Nanjing Medical University Not yet recruiting No outcome recorded
— NCT07694596 Background Jun 2026 → Apr 2028 expected cognitive disorder, type 2 diabetes mellitus University of Primorska Active not recruiting No outcome recorded
— NCT07391267 Background Feb 2026 → Dec 2028 expected chronic kidney disease, metabolic dysfunction-associated steatotic liver disease Institute of Liver and Biliary Sciences, India Not yet recruiting No outcome recorded
— NCT07335900 Background Dec 2025 → Dec 2026 expected aortic valve stenosis RenJi Hospital Recruiting No outcome recorded
— NCT07070765 Comparator Dec 2025 → Oct 2028 expected breast cancer University of Aberdeen Recruiting No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2024-06-12 AstraZeneca Farxiga approved in the US for the treatment of paediatric type-2 diabetes astrazeneca.com ↗
2023-11-03 AstraZeneca Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial astrazeneca.com ↗

Evidence & citations 24 cited values

Every value below carries the sentence it was read from. 621 sources stand behind the page.

FieldValueCited text
Known as Dapagliflozin “The study intervention will be a heart failure with reduced ejection fraction (HFrEF) polypill consisting of bisoprolol (beta-blocker), losartan (ARB), eplerenone (MRA), and...” NCT07569640 ↗
607

“HFrEF polypill strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone...” NCT06831864 ↗

“BACKGROUND AND OBJECTIVES: To establish pharmacokinetic bioequivalence and assess the safety of a single-dose administration of fixed-dose combination (FDC) tablet containing...” PMID 42270920 ↗ Jun 2026

“A total of 235 patients with inadequate response to metformin (≥1000 mg/day) plus linagliptin (5 mg/day) were randomized to receive either dapagliflozin/linagliptin fixed-dose...” PMID 39375869 ↗ Oct 2024

“Participants randomized to the intervention group will receive empagliflozin (10 mg once daily, with optional titration to 25 mg according to clinical judgement and...” NCT07694596 ↗

“Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin...” NCT06142474 ↗

“This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined...” NCT07147114 ↗

“The primary objective of the study is to examine the effect of combination therapy with pioglitazone (15 mg) plus dapagliflozin (10 mg) versus placebo on hospitalization for...” NCT03794518 ↗

“The specific agent (e.g., dapagliflozin or empagliflozin) and dose will be selected based on safety data and clinical guidelines applicable to patients with end-stage renal...” NCT06929169 ↗

“Sequential discontinuation of angiotensin receptor-neprilysin inhibitor (ARNI; e.g., sacubitril/valsartan) and sodium-glucose cotransporter-2 inhibitor (SGLT2i; e.g.,...” NCT07631156 ↗

“Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.” PMID 39768420 ↗ Dec 2024

“Dapagliflozin is a novel highly selective SGLT2 inhibitor that improves glycemic control by reducing renal glucose reabsorption leading to urinary glucose excretion.” NCT02338193 ↗

“All patients will be started on an SGLT2i (Empagliflozin or Dapagliflozin) and a betablocker (Metoprolol, Bisoprolol or Carvedilol) right after study inclusion.” NCT05637853 ↗

“Chemical Name: Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) Class: SGLT2 Inhibitors” NCT06449235 ↗

“Patients will be randomized 1:1 in blocks of 6 patients to either Dapagliflozin 10 mg daily or placebo within 1 months prior to the scheduled TAVR therapy.” NCT05241431 ↗

“the study aims to investigate the effect of dapagliflozin, a SGLT2 inhibitor, on glucose flux, lipolysis and exercise in patients with type 2 diabetes.” NCT04219124 ↗

“In this study, patients received standard clinical doses (e.g., dapagliflozin 5-10 mg once daily or empagliflozin 10-25 mg once daily) for 6 months.” NCT07539584 ↗

“The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.” NCT07070765 ↗

“Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction” NCT07488689 ↗

“receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin)” NCT04419337 ↗

“adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.” NCT06147271 ↗

“Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast” NCT05403281 ↗

“On the basis of standard cancer treatment, take dapagliflozin for at least three months, once a day, 10 mg each time.” NCT07272057 ↗

“where subjects will either begin study provided dapagliflozin 10 mg or continue on their regularly prescribed SGLT2i” NCT06150924 ↗

“Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia in type 2 diabetes by increasing renal glucose excretion.” PMID 23668478 ↗ Jun 2013

“The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days.” NCT06615674 ↗

“MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes” NCT03444584 ↗

“Oral ACEI/ARB (e.g., valsartan capsules 80mg qd or 150mg qd) + Dapagliflozin (10 or 20mg orally once a day)” NCT07356388 ↗

“Investigations were performed before and after a 12-week treatment with the SGLT2 inhibitor, dapagliflozin.” PMID 32514450 ↗ Nov 2019

“ATB-U101 is a fixed-dose combination tablet containing Olmesartan medoxomil 40 mg and Dapagliflozin 10 mg.” NCT07590466 ↗

“Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.” NCT04798222 ↗

“either 12 months of oral SGLT2 inhibitor therapy (Dapagliflozin 10 mg once daily) or a matching placebo” NCT07682350 ↗

“SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) - recommended for people with T2D + CKD” NCT07391267 ↗

“Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State.” PMID 31992459 ↗ Jan 2020

“Maximal labelled or tolerated dose of ACEi/ ARB and a steady dose of SGLT2i (10mg/d of dapagliflozin).” NCT06676384 ↗

“Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together” NCT04972539 ↗

“For the SGLT2 inhibitor group, empagliflozin 10mg or dapagliflozin 10mg once daily is administered.” NCT05975528 ↗

“the second group will receive an SGLT2 inhibitor (dapagliflozin or empagliflozin 10 mg once daily)” NCT07563647 ↗

“empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage” NCT05278962 ↗

“The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.” NCT04400760 ↗

“The glucose-lowering component will consist of dapagliflozin at a fixed dose of 10 mg.” NCT07679828 ↗

“the SGLT2 inhibitor (dapagliflozin 10 mg once daily or empagliflozin 10 mg once daily)” NCT07572032 ↗

“CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition” NCT03601910 ↗

“10 mg dapagliflozin/100 mg sitagliptin FDC (Treatment A) with their ICs (Treatment B)” PMID 39179458 ↗ Aug 2024

“Group dapagliflozin: stander treatment of Type 2 diabetes mellitus plus dapagliflozin” NCT06117137 ↗

“Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg” NCT04697485 ↗

“Withdrawal of spironolactone or eplerenone and dapagliflozin or empagliflozin” NCT06091475 ↗

“Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)” NCT04035031 ↗

“Dapagliflozin 10 mg once daily (QD) or Empagliflozin 10 mg once daily (QD)” NCT07105917 ↗

“Dapagliflozin will be started at 10 mg daily per oral administration” NCT04196231 ↗

“SGLT2 inhibitor: dapagliflozin or empagliflozin at 10 mg per day” NCT07513883 ↗

“Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD” NCT04544319 ↗

“Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg” NCT02946632 ↗

“Dapagliflozin 10mg +sitagliptin 100mg combination drug” NCT06875193 ↗

“to receive dapagliflozin (10 mg once daily) or placebo” PMID 32970396 ↗ Sep 2020

“an SGLT2 inhibitor (empagliflozin or dapagliflozin)” NCT06930092 ↗

“subgroup 3A- addition of dapagliflozin 10 mg/day” NCT03804411 ↗

“Either empagliflozin or dapagliflozin 10 mg/day” NCT05989503 ↗

“Empagliflozin, dapagliflozin, or canagliflozin” NCT05390892 ↗

“Dapagliflozin/Metformin (Xigduo XR) 10/1000mg” NCT03826641 ↗

“SGLT2i can be dapagliflozin or empagliflozin.” NCT07331220 ↗

“Dapagliflozin (Forxiga), 10 mg tablet daily.” NCT07392151 ↗

“10 mg of Dapagliflozin orally once daily” NCT05993897 ↗

“Metformin, Dapagliflozin and Saxagliptin” NCT03700801 ↗

“such as dapagliflozin and empagliflozin” NCT07335900 ↗

“Dapagliflozin (SGLTII-Inhibitor, 10 mg)” NCT04027023 ↗

“Dapagliflozin 10mg + Linagliptin 5mg” NCT07034781 ↗

“Dapagliflozin 10mg + Linagliptin 5mg” NCT07044765 ↗

“SGLT-2 inhibitor (dapagliflozin)” NCT05965934 ↗

“Dapagliflozin (Forxiga) 10mg” NCT04084184 ↗

“Dapagliflozin 10mg (Farxiga)” NCT05541484 ↗

“dapagliflozin (5-10mg daily)” NCT02528019 ↗

“dapagliflozin (10 mg daily)” NCT05346653 ↗

“dapagliflozin (Farxiga®)” NCT07325435 ↗

“Dapagliflozin 10 mg” NCT06647745 ↗

“Drug: Dapagliflozin” NCT03199053 ↗

“Dapagliflozin 10mg” NCT05411965 ↗

“Dapagliflozin” NCT03887416 ↗

“Dapagliflozin” NCT02919059 ↗

“dapagliflozin” NCT05737186 ↗

“dapagliflozin” NCT04882358 ↗

NCT02700334 ↗

NCT01002807 ↗

NCT05424315 ↗

NCT02719756 ↗

NCT06639087 ↗

NCT03168295 ↗

NCT01498185 ↗

NCT04475042 ↗

NCT07239570 ↗

NCT05521984 ↗

NCT02253121 ↗

NCT07018622 ↗

NCT03871621 ↗

NCT05321706 ↗

NCT06344247 ↗

NCT07555106 ↗

NCT04570865 ↗

NCT05944016 ↗

NCT06268873 ↗

NCT04545411 ↗

NCT06491680 ↗

NCT04298229 ↗

NCT02919059 ↗

NCT06269484 ↗

NCT03721874 ↗

NCT01165268 ↗

NCT05748925 ↗

NCT04796428 ↗

NCT00842556 ↗

NCT04356742 ↗

NCT01072578 ↗

NCT03344341 ↗

NCT00831779 ↗

NCT00643851 ↗

NCT02613897 ↗

NCT06350123 ↗

NCT05710367 ↗

NCT01294423 ↗

NCT05601336 ↗

NCT02413398 ↗

NCT02879409 ↗

NCT02798757 ↗

NCT04887935 ↗

NCT06127433 ↗

NCT04783870 ↗

NCT05390307 ↗

NCT04170998 ↗

NCT05105698 ↗

NCT04492722 ↗

NCT05196347 ↗

NCT07239011 ↗

NCT01294436 ↗

NCT01042977 ↗

NCT05162690 ↗

NCT00736879 ↗

NCT06365541 ↗

NCT05719714 ↗

NCT02973477 ↗

NCT04696185 ↗

NCT04195243 ↗

NCT03592667 ↗

NCT03387683 ↗

NCT06919523 ↗

NCT02547935 ↗

NCT07214818 ↗

NCT07404137 ↗

NCT02327039 ↗

NCT05179356 ↗

NCT03970044 ↗

NCT03619213 ↗

NCT02981069 ↗

NCT02577159 ↗

NCT03762850 ↗

NCT02551874 ↗

NCT01257412 ↗

NCT03877224 ↗

NCT01095653 ↗

NCT07403955 ↗

NCT04965935 ↗

NCT07678203 ↗

NCT05236998 ↗

NCT06750458 ↗

NCT06778330 ↗

NCT02475070 ↗

NCT02229396 ↗

NCT01730534 ↗

NCT07323524 ↗

NCT03152084 ↗

NCT01195662 ↗

NCT02597049 ↗

NCT01135446 ↗

NCT02397421 ↗

NCT01055691 ↗

NCT04242758 ↗

NCT06762964 ↗

NCT01055652 ↗

NCT01646320 ↗

NCT03030235 ↗

NCT02501616 ↗

NCT02681094 ↗

NCT06907251 ↗

NCT04782245 ↗

NCT04564742 ↗

NCT07516847 ↗

NCT04724837 ↗

NCT07363707 ↗

NCT04534270 ↗

NCT00726505 ↗

NCT02653482 ↗

NCT04350593 ↗

NCT07077525 ↗

NCT03180489 ↗

NCT06510270 ↗

NCT04575675 ↗

NCT02235298 ↗

NCT05250752 ↗

NCT05179668 ↗

NCT06719661 ↗

NCT06420167 ↗

NCT02279407 ↗

NCT04531397 ↗

NCT00546741 ↗

NCT02420392 ↗

NCT03202563 ↗

NCT04794517 ↗

NCT06887062 ↗

NCT06433479 ↗

NCT07595289 ↗

NCT07515391 ↗

NCT07020377 ↗

NCT04255238 ↗

NCT05797935 ↗

NCT04930549 ↗

NCT03364985 ↗

NCT07204743 ↗

NCT05014594 ↗

NCT01535677 ↗

NCT02313220 ↗

NCT02096705 ↗

NCT01217892 ↗

NCT02919345 ↗

NCT05141552 ↗

NCT02608905 ↗

NCT04080518 ↗

NCT02981966 ↗

NCT02383238 ↗

NCT03499704 ↗

NCT06499948 ↗

NCT06009874 ↗

NCT07033585 ↗

NCT01095666 ↗

NCT06421870 ↗

NCT03169959 ↗

NCT06759909 ↗

NCT05392959 ↗

NCT05762952 ↗

NCT04200586 ↗

NCT07245069 ↗

NCT02471404 ↗

NCT07187570 ↗

NCT02460978 ↗

NCT06427226 ↗

NCT06626737 ↗

NCT03919656 ↗

NCT06373523 ↗

NCT07311551 ↗

NCT03714594 ↗

NCT06576375 ↗

NCT01392677 ↗

NCT06721442 ↗

NCT05914857 ↗

NCT06398977 ↗

NCT06317051 ↗

NCT05713851 ↗

NCT00528372 ↗

NCT07436663 ↗

NCT07469722 ↗

NCT04739215 ↗

NCT02338921 ↗

NCT05816733 ↗

NCT06759077 ↗

NCT02719132 ↗

NCT04304560 ↗

NCT06065280 ↗

NCT05505994 ↗

NCT06263673 ↗

NCT06187493 ↗

NCT04730947 ↗

NCT02532855 ↗

NCT02796170 ↗

NCT06589765 ↗

NCT05989347 ↗

NCT02765204 ↗

NCT04120623 ↗

NCT06147518 ↗

NCT03190694 ↗

NCT00554450 ↗

NCT05418465 ↗

NCT05957887 ↗

NCT00972244 ↗

NCT07610174 ↗

NCT03968224 ↗

NCT05764057 ↗

NCT05459701 ↗

NCT05591235 ↗

NCT06434025 ↗

NCT06897605 ↗

NCT05225077 ↗

NCT06711185 ↗

NCT06772168 ↗

NCT05139914 ↗

NCT06087835 ↗

NCT03313752 ↗

NCT02372955 ↗

NCT02610088 ↗

NCT04595370 ↗

NCT06286878 ↗

NCT06783166 ↗

NCT05042505 ↗

NCT02911792 ↗

NCT06785116 ↗

NCT03006471 ↗

NCT05262257 ↗

NCT06982079 ↗

NCT06562582 ↗

NCT04393246 ↗

NCT05704088 ↗

NCT06651021 ↗

NCT04706637 ↗

NCT04640493 ↗

NCT04778787 ↗

NCT04249778 ↗

NCT07351864 ↗

NCT02695810 ↗

NCT02635386 ↗

NCT05986136 ↗

NCT05066516 ↗

NCT04885712 ↗

NCT06405178 ↗

NCT05345327 ↗

NCT05676684 ↗

NCT05565976 ↗

NCT02914691 ↗

NCT05590143 ↗

NCT04330079 ↗

NCT06155604 ↗

NCT04764097 ↗

NCT04401904 ↗

NCT04591639 ↗

NCT07351643 ↗

NCT07598864 ↗

NCT06612086 ↗

NCT07399470 ↗

NCT05058859 ↗

NCT00660907 ↗

NCT07310433 ↗

NCT06063109 ↗

NCT01525238 ↗

NCT07254572 ↗

NCT01662999 ↗

NCT03074630 ↗

NCT04363697 ↗

NCT04234867 ↗

NCT06619600 ↗

NCT06690723 ↗

NCT04792190 ↗

NCT04451837 ↗

NCT03961659 ↗

NCT00930865 ↗

NCT03766724 ↗

NCT02419612 ↗

NCT00538174 ↗

NCT03658031 ↗

NCT05045274 ↗

NCT04923295 ↗

NCT05468203 ↗

NCT06979388 ↗

NCT06326034 ↗

NCT07405216 ↗

NCT07297589 ↗

NCT02433678 ↗

NCT06528405 ↗

NCT04170543 ↗

NCT05308160 ↗

NCT01877889 ↗

NCT07491042 ↗

NCT00680745 ↗

NCT05194592 ↗

NCT03982238 ↗

NCT04213677 ↗

NCT05938712 ↗

NCT03887416 ↗

NCT02725593 ↗

NCT00855166 ↗

NCT07539259 ↗

NCT03269058 ↗

NCT02459353 ↗

NCT00859898 ↗

NCT03423355 ↗

NCT05833958 ↗

NCT02558270 ↗

NCT04620590 ↗

NCT04818034 ↗

NCT06233045 ↗

NCT07482943 ↗

NCT05343078 ↗

NCT02751398 ↗

NCT00908271 ↗

NCT07082114 ↗

NCT06327815 ↗

NCT06535529 ↗

NCT07120828 ↗

NCT03982381 ↗

NCT06922656 ↗

NCT01619059 ↗

NCT07342764 ↗

NCT07222917 ↗

NCT05457933 ↗

NCT06915870 ↗

NCT07076615 ↗

NCT04287387 ↗

NCT04542291 ↗

NCT04707261 ↗

NCT00839683 ↗

NCT03377335 ↗

NCT05109949 ↗

NCT00984867 ↗

NCT07684326 ↗

NCT01439854 ↗

NCT02518945 ↗

NCT05254626 ↗

NCT06012266 ↗

NCT02113241 ↗

NCT04780438 ↗

NCT03036150 ↗

NCT07662044 ↗

NCT03556033 ↗

NCT05795400 ↗

NCT02956811 ↗

NCT07614230 ↗

NCT02564926 ↗

NCT03216278 ↗

NCT05998525 ↗

NCT07338331 ↗

NCT06304857 ↗

NCT03089333 ↗

NCT01068756 ↗

NCT07026968 ↗

NCT07303556 ↗

NCT03398577 ↗

NCT04445714 ↗

NCT05406505 ↗

NCT05268926 ↗

NCT05516498 ↗

NCT07662109 ↗

NCT03710460 ↗

NCT05570305 ↗

NCT02211742 ↗

NCT06192108 ↗

NCT04860011 ↗

NCT07174687 ↗

NCT03537131 ↗

NCT06851962 ↗

NCT05998837 ↗

NCT00904176 ↗

NCT04333823 ↗

NCT06740786 ↗

NCT03660683 ↗

NCT05050500 ↗

NCT03361098 ↗

NCT06281899 ↗

NCT03959501 ↗

NCT05915949 ↗

NCT05618223 ↗

NCT06845163 ↗

NCT05848102 ↗

NCT02157298 ↗

NCT04856969 ↗

NCT06241638 ↗

NCT06642623 ↗

NCT00263276 ↗

NCT06954090 ↗

NCT07491718 ↗

NCT02592421 ↗

NCT05852704 ↗

NCT04717986 ↗

NCT05735197 ↗

NCT02962492 ↗

NCT06174753 ↗

NCT03419624 ↗

NCT04956809 ↗

NCT06668389 ↗

NCT06890143 ↗

NCT05776043 ↗

NCT00976495 ↗

NCT06307652 ↗

NCT05217654 ↗

NCT00688493 ↗

NCT04707352 ↗

NCT04014192 ↗

NCT05420285 ↗

NCT02520518 ↗

NCT07280585 ↗

NCT05685394 ↗

NCT05440591 ↗

NCT07295223 ↗

NCT05330013 ↗

NCT05884866 ↗

NCT07396844 ↗

NCT06972732 ↗

NCT04869124 ↗

NCT03565458 ↗

NCT06888505 ↗

NCT02616666 ↗

NCT06820567 ↗

NCT03036124 ↗

NCT02284893 ↗

NCT04956263 ↗

NCT06942910 ↗

NCT05359263 ↗

NCT07624305 ↗

NCT06748105 ↗

NCT07333742 ↗

NCT00528879 ↗

NCT03338855 ↗

NCT01031680 ↗

NCT01137474 ↗

NCT06341842 ↗

NCT06374043 ↗

NCT06532682 ↗

NCT06383832 ↗

NCT06677060 ↗

NCT05025735 ↗

NCT06000462 ↗

NCT06012279 ↗

NCT05435235 ↗

NCT06140537 ↗

NCT06642272 ↗

NCT02987738 ↗

NCT04991571 ↗

NCT06742723 ↗

NCT06415773 ↗

NCT06578520 ↗

NCT05788276 ↗

NCT03801642 ↗

NCT02969798 ↗

NCT03608358 ↗

NCT00357370 ↗

NCT06072326 ↗

NCT05849766 ↗

NCT05621551 ↗

NCT05717257 ↗

NCT06442280 ↗

NCT05792540 ↗

NCT05886088 ↗

NCT07589075 ↗

NCT06364930 ↗

NCT02426541 ↗

NCT06610526 ↗

NCT07392788 ↗

NCT03723252 ↗

NCT05965440 ↗

NCT02682563 ↗

NCT04385589 ↗

NCT04004793 ↗

NCT05374291 ↗

NCT03331289 ↗

NCT05782972 ↗

NCT03782259 ↗

NCT02925559 ↗

NCT05335629 ↗

NCT06026787 ↗

NCT06113900 ↗

NCT03007329 ↗

NCT02811484 ↗

NCT07344922 ↗

NCT05226897 ↗

NCT07273838 ↗

NCT05606718 ↗

NCT04806633 ↗

NCT05550441 ↗

NCT02777073 ↗

NCT07235280 ↗

NCT00683878 ↗

NCT05443932 ↗

NCT05174052 ↗

NCT03704818 ↗

NCT05429593 ↗

NCT05159882 ↗

NCT06054035 ↗

NCT02887677 ↗

NCT07331727 ↗

NCT05849220 ↗

NCT02371187 ↗

NCT07056699 ↗

NCT02582840 ↗

NCT05310916 ↗

NCT04743453 ↗

NCT00562250 ↗

NCT05741658 ↗

NCT04258371 ↗

NCT03899402 ↗

NCT00673231 ↗

NCT07025629 ↗

NCT02268214 ↗

NCT05558098 ↗

NCT02582814 ↗

NCT06560801 ↗

NCT04899349 ↗

NCT07108985 ↗

NCT02984644 ↗

NCT01606007 ↗

NCT05966818 ↗

NCT01156246 ↗

NCT03178591 ↗

NCT00663260 ↗

NCT07083388 ↗

NCT07083401 ↗

NCT02325206 ↗

NCT06111768 ↗

NCT03877237 ↗

NCT02585804 ↗

NCT02965443 ↗

NCT03316131 ↗

NCT06111443 ↗

NCT04340908 ↗

NCT06812429 ↗
Known as A51R1 “Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together” NCT04972539 ↗
Known as ATB-1012 “ATB-1011 (Olmetec, Olmesartan medoxomil 40 mg) and ATB-1012 (Forxiga, Dapagliflozin 10 mg) will be co-administered as a single oral dose under fasting conditions (minimum 10...” NCT07590466 ↗
Known as BMS -512148 “The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated...” NCT01606007 ↗
1

NCT00162305 ↗
Known as BMS-51248 “The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control” NCT00643851 ↗
Known as CKD-380 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03601910 ↗
Known as DAPA “Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the...” NCT05792540 ↗
28

“The overarching hypothesis of this study is that vildagliptin (vilda) as add on therapy to metformin (met) in Egyptian type 2 diabetic obese patient will produce an equal, if...” NCT07077525 ↗

“FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure...” NCT04956809 ↗

“AIMS: To investigate the potential synergistic effects of combined exenatide (EXE) and dapagliflozin (DAPA) versus (PLAC) placebo and DAPA on hepatocellular lipid (HCL)...” PMID 33464703 ↗ Feb 2021

“treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and...” NCT04730947 ↗

“To investigate the effect of the SGLT2 inhibitor, dapagliflozin (DAPA), on cardiac function and the metabolic and hormonal response to moderate exercise in people with type 2 diabetes.” PMID 36274035 ↗ Mar 2023

“We evaluated the effects of dapagliflozin (DAPA) on measures of cardiovascular autonomic neuropathy (CAN), cardiac function, and glucose variability (GV) in T2D.” PMID 34024686 ↗ May 2021

“Dapagliflozin (DAPA) has shown renal and cardiometabolic benefits in nontransplanted patients with chronic kidney disease.” PMID 42102257 ↗ May 2026

“Dapagliflozin (DAPA) is an inhibitor of sodium-glucose cotransporter 2 prescribed for type 2 diabetes mellitus.” PMID 30689697 ↗ Apr 2019

“The efficacy of once-weekly exenatide (EQW) and dapagliflozin (DAPA) alone and coadministered” PMID 34097062 ↗ Sep 2021

“Dapagliflozin (DAPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor” NCT06427226 ↗

“Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin” PMID 39865301 ↗ Jan 2025

“dapagliflozin (DAPA), 10 mg” PMID 35235659 ↗ Jun 2022

“Drug: Dapagliflozin (DAPA)” NCT07076615 ↗

“Dapagliflozin (DAPA)” NCT06748105 ↗

“Dapagliflozin (DAPA)” NCT06820567 ↗

“Dapagliflozin (DAPA)” NCT06812429 ↗

“Dapagliflozin (DAPA)” NCT07614230 ↗

“Dapagliflozin (DAPA)” NCT07120828 ↗

“Dapagliflozin (DAPA)” NCT07539259 ↗

“Dapagliflozin (DAPA)” NCT06922656 ↗

“Dapagliflozin (DAPA)” NCT07082114 ↗

“Dapagliflozin (DAPA)” NCT06897605 ↗

“Dapagliflozin (DAPA)” NCT06759077 ↗

“Dapagliflozin (DAPA)” NCT06721442 ↗

“Dapagliflozin (DAPA)” NCT06759909 ↗

“Dapagliflozin (DAPA)” NCT06626737 ↗

“Dapagliflozin (DAPA)” NCT07020377 ↗

“Dapagliflozin (DAPA)” NCT06907251 ↗
Known as dapagliflozin (Farxiga) “dapagliflozin (Farxiga®)” NCT07325435 ↗
Known as Dapagliflozin 10mg (Farxiga) “Dapagliflozin 10mg (Farxiga)” NCT05541484 ↗
Known as Dapagliflozin propanediol “Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.” NCT04869124 ↗
1

“Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)” NCT05764057 ↗
Known as Dapagliflozin/metformin IR FDC ClinicalTrials.gov intervention name — accepted as the source's own label NCT01535677 ↗
Known as dapagliflozine “Intervention: Dapagliflozine 10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment.” NCT04127084 ↗
3

“SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally” NCT06759077 ↗

“Drug: dapagliflozine” NCT07351864 ↗

NCT07083232 ↗
Known as Dapagliglozin “The 2019 DAPA-HF trial studied whether the addition of the SCLT-2 inhibitor dapagliglozin could benefit patients with heart failure with reduced ejection fraction (HFrEF),...” NCT04570865 ↗
Known as Diglifloz “Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).” NCT05966818 ↗
Known as Farxiga “The investigational medicinal product (IMP) is Dapagliflozin 10 MG Oral Tablet [Farxiga] given once daily (film coated tablets, oral use).” NCT03887416 ↗
17

“Subjects receive once daily 10 mg of oral dapagliflozin (Farxiga) for 14 days (or until discharge).” NCT07273838 ↗

“The patients assigned to the Dapagliflozin group will take Farxiga Pill 10mg for 6 months.” NCT05194592 ↗

“Dapagliflozin 10 mg [Farxiga] for 3 months after catheter ablation of atrial fibrillation” NCT06111443 ↗

“Dapagliflozin therapy (Farxiga®, 10 mg tablets) is administered orally once daily” NCT06890143 ↗

“Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg” NCT04697485 ↗

“Drug: Dapagliflozin 10 milligrams [Farxiga]” NCT04591639 ↗

“Dapagliflozin 10 MG Oral Tablet [Farxiga]” NCT07025629 ↗

“Drug: Dapagliflozin 10 MG [Farxiga]” NCT05250752 ↗

“Drug: Dapagliflozin 10 MG [Farxiga]” NCT05719714 ↗

“Farxiga® (dapagliflozin) 10 mg” NCT07033585 ↗

“Dapagliflozin 10 MG [Farxiga]” NCT04620590 ↗

“Dapagliflozin 10 MG [Farxiga]” NCT04545411 ↗

“Dapagliflozin 10 MG [Farxiga]” NCT05225077 ↗

“Dapagliflozin 10 MG [Farxiga]” NCT04739215 ↗

“Dapagliflozin 10 MG [Farxiga]” NCT05179356 ↗

“Dapagliflozin Farxiga®” NCT05849766 ↗

“Dapagliflozin, Farxiga” NCT02551874 ↗
Known as FARXIGA1 “Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)” NCT05764057 ↗
Known as Forxiga “each group was administered either a single dose of IN-C009 (FCDP, dapagliflozin 10mg/linagliptin 5 mg) (HK inno.N., Seoul, Korea) or co-administration of a single dose of...” NCT05066516 ↗
27

“The goal of this clinical trial is to find out whether 12 months of treatment with the SGLT2 inhibitor Forxiga® (dapagliflozin 10 mg once daily), compared with placebo, can...” NCT07682350 ↗

“ATB-1011 (Olmetec, Olmesartan medoxomil 40 mg) and ATB-1012 (Forxiga, Dapagliflozin 10 mg) will be co-administered as a single oral dose under fasting conditions (minimum 10...” NCT07590466 ↗

“Dapagliflozin tablet 10 mg relative to Forxiga® film-coated tablets 10 mg, of AstraZeneca pharmaceuticals LP, Mount Vernon, Indiana, USA in healthy Thai volunteers under...” NCT06233045 ↗

“Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia” NCT06615674 ↗

“The goal of this single arm, prospective study is to test the therapeutic response of oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks in non-diabetic MAFLD patients.” NCT05782972 ↗

“Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Dapagliflozin (Forxiga) 10 mg, one capsule per day orally.” NCT04739215 ↗

“FORXIGA（Dapagliflozin Tablets), manufacturer/marketer: AstraZeneca, salt composition: Dapagliflozin (10mg), one tablet once and once a day.” NCT05848102 ↗

“The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.” NCT04004793 ↗

“patients receiving dapagliflozin (Forxiga; MP-002596) at a dose of 10 mg / day per os in addition to the current therapy” NCT04778787 ↗

“Patients will receive Dapagliflozin 10 mg once daily orally for 12 weeks (Forxiga® AstraZeneca company)” NCT06576375 ↗

“Drug: Dapagliflozin (DAPA) Dose: 10 mg once daily Route: Oral Other Name(s): Forxiga” NCT07076615 ↗

“The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets” NCT02616666 ↗

“dapagliflozin (FORXIGA) might improve lipoprotein metabolism” NCT02577159 ↗

“oral dapagliflozin (Forxiga®) treatment versus placebo” NCT05179356 ↗

“SGLT2is- Dapagliflozin (Forxiga): 10 mg/d, oral drug” NCT05710367 ↗

“Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)” NCT05764057 ↗

“Dapagliflozin (Forxiga), 10 mg tablet daily.” NCT07392151 ↗

“Dapagliflozin 10 MG [Forxiga]” NCT04080518 ↗

“Dapagliflozin (Forxiga) 10mg” NCT04084184 ↗

“Dapagliflozin (Forxiga®)” NCT06072326 ↗

“Dapagliflozin (Forxiga®)” NCT03423355 ↗

“Dapagliflozin (Forxiga®)” NCT06054035 ↗

“Dapagliflozin (Forxiga)” NCT06888505 ↗

“Dapagliflozin (Forxiga)” NCT06690723 ↗

“Dapagliflozin (Forxiga)” NCT07254572 ↗

“Dapagliflozin (Forxiga)” NCT06612086 ↗

“dapagliflozin：Forxiga®️” NCT06344247 ↗
Known as MP-002596 “patients receiving dapagliflozin (Forxiga; MP-002596) at a dose of 10 mg / day per os in addition to the current therapy” NCT04778787 ↗
Known as SGLT2 inhibitor ClinicalTrials.gov intervention name — accepted as the source's own label NCT04505774 ↗
Known as THP-00101 “THP-00101 (Dapagliflozin) 10mg” NCT06063109 ↗
Action Inhibit “Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2” PMID 19114612 ↗ Dec 2008
Modality Small molecule “SGLT2 inhibitor dapagliflozin” PMID 42467086 ↗ Jul 2026
Route Oral “Tablets, Oral” NCT00263276 ↗
Target SLC5A2 “a selective inhibitor of sodium-glucose cotransporter 2” PMID 30415602 ↗ Nov 2018